Clinical Trial Update: Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating dual-targeting CAR-NK cells directed at mesothelin and MUC1 for advanced pancreatic ductal adenocarcinoma is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Dual-targeting CAR-NK cells targeting mesothelin (MSLN) and MUC1 (CAR-NK cells targeting mesothelin and MUC1)

Snippet

Sponsor: Beijing Biotech | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease | Phase 1, Phase 2 | Status: RECRUITING